Patent · US Active

Pro- and anti-angiogenic treatments

US9447418B2 · kind B2 · utility

0Cited by

2References

5Claims

0Family size

Assignee

The University of Bristol · GB

Inventors

David Bates · Bristol, GB
Steven Harper · Roma, IT
Dawid Nowak · Dublin, IE

Key dates

Filing date	Mar 10, 2008
Grant date	Sep 20, 2016
Priority date	—
Expiry date	May 18, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/33
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides a method of selectively pro-oranti-angiogenic treatment of a mammalian subject, comprising site-specific control of alternative splicing during processing of VEGF pre-mRNA transcribed from the C terminal exon 8 of the VEGF gene using controlling agents for the splicing, wherein one or more controlling agent which favors proximal splice site (PSS) splicing in said processing is used in the pro-angiogenic treatment and one or more controlling agent which favors distal splice site (DSS) splicing in said processing is used in the anti-angiogenic treatment.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.